Natco Pharma has announced the successful completion of regulatory inspection by the US Food and Drug Administration of its active pharmaceutical ingredient facility in Chennai. The inspection was conducted between July 8 and 12. The regulatory audit resulted in zero observations, it said. Shares of Natco Pharma slipped 0.23 per cent at ₹526.80 on the NSE.
Company news: Natco Pharma
Published on
July 15, 2019 15:47